Immune Response News and Research

RSS

Novel technology to diagnose Alzheimer's disease before symptoms appear

UT Southwestern Medical Center scientists have helped develop a novel technology to diagnose Alzheimer's disease from blood samples long before symptoms appear.

14 Feb 2011

Protective immunity against HIV can be achieved without presence of virus neutralizing antibodies in the blood

New research shows that protective immunity against HIV can be achieved without the presence of virus neutralizing antibodies in the blood. The study, published by Cell Press in the February issue of the journal Immunity, demonstrates that a vaccine which stimulates production of specific anti-HIV antibodies in the vaginal tissue was sufficient to protect monkeys from exposure to live virus.

11 Feb 2011

Vaccinating through salivary glands may provide protection against wide range of diseases

If you don't like shots or needles, you're in luck. New research published online in The FASEB Journal gives the development of new oral vaccinations a shot in the arm thanks to discoveries involving the salivary glands of mice. In addition, this research report also offers a tantalizing glimpse of vaccines that could prevent infection at mucosal surfaces, even if direct injections into the body fail to cause immunity. This technique may be effective for a wide range of diseases from influenza to cholera.

11 Feb 2011

Blocking interleukin 15 may help restore oral tolerance to gluten

Blocking a factor that can activate the human immune response against intestinal bacteria or certain foods could prevent the development of celiac disease in those most at risk, researchers report in the journal Nature.

11 Feb 2011

Avian flu vaccine stockpiled in 2004 still useful

A stockpiled vaccine designed to fight a strain of avian flu that circulated in 2004 can be combined with a vaccine that matches the current strain of bird flu to protect against a potential pandemic, researchers from Saint Louis University's Center for Vaccine Development have found.

10 Feb 2011

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

Liquidia Technologies today announced a collaboration with the PATH Malaria Vaccine Initiative (MVI) to explore the use of the company's PRINT® particle technology to design next generation malaria vaccines. PRINT technology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process, and will be used to deliver a protein in combination with immune stimulating molecules.

10 Feb 2011

Topical cream used to treat skin diseases activates two distinct neuronal signaling pathways

Scratching deep beneath the surface, a team of researchers from the University of California, San Diego School of Medicine and three South Korean institutions have identified two distinct neuronal signaling pathways activated by a topical cream used to treat a variety of skin diseases. One pathway produces the therapeutic benefit; the other induces severe itching as a side effect.

9 Feb 2011

Researchers identify immune cell population that acts as body's border patrol with the outside world

So-called barrier sites -- the skin, gut, lung - limit the inner body's exposure to allergens, pollutants, viruses, bacteria, and parasites. Understanding how the immune system works in these external surfaces has implications for understanding such inflammatory diseases as asthma, psoriasis, IBD, and food allergies, all of which occur at the body's barriers.

8 Feb 2011

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of electroporation without contacting the skin, is highlighted in a paper published in the scientific journal Human Vaccines.

7 Feb 2011

Technique that cleared mouse of HIV-like virus sparks hope for new therapy

In a breakthrough, Australian researchers have developed a method to boost the immune system. This technique is seen to be capable of clearing an “HIV-like” infection from a mouse. This could in future lead to a cure for HIV and other chronic viral infections in humans. The findings from Melbourne’s Walter and Eliza Hall Institute are centred on a naturally occurring cell signalling hormone called interleukin-7 (IL-7).

6 Feb 2011

Cell signaling hormone boosts immune response to clear HIV-like infection

Australian scientists have successfully cleared a HIV-like infection from mice by boosting the function of cells vital to the immune response.

4 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

Immune protein exacerbates skin cancer due to sun exposure: Study

An unexpected immune protein exacerbates cancer due to sun exposure, report researchers in the January 27th issue of Nature. The study suggests that drugs blocking the protein might halt tumor growth in skin cancer patients.

3 Feb 2011

Researchers discover potential vaccine capable of reducing H. pylori colonization

A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori -- a known cause of gastritis, ulcer disease and cancer.

2 Feb 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.

2 Feb 2011

Scientists discover breast cancer cells that dodge immune system, promote tumor growth

Scientists discovered a new way breast cancer cells dodge the immune system and promote tumor growth, providing a fresh treatment target in the fight against the disease. While comparable mechanisms to avoid the immune system have been identified in mice with breast and other cancers, the study tested human breast tumor cells, putting researchers closer to understanding how the disease progresses in real patients.

2 Feb 2011

New compound appears to prevent pain crises in sickle cell disease: GHSU

A new compound appears to prevent the traffic jam of cells that causes debilitating pain crises and associated mortality in sickle cell disease, Georgia Health Sciences University researchers report.

1 Feb 2011

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Medicago, a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate.

1 Feb 2011

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase II human clinical trial with its H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

1 Feb 2011

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce that the first group of patients receiving the lowest dose of SCIB1 in the Phase I clinical trial has been evaluated by the Cohort Review Committee.

31 Jan 2011

Immune Response News and Research

Novel technology to diagnose Alzheimer's disease before symptoms appear

Protective immunity against HIV can be achieved without presence of virus neutralizing antibodies in the blood

Vaccinating through salivary glands may provide protection against wide range of diseases

Blocking interleukin 15 may help restore oral tolerance to gluten

Avian flu vaccine stockpiled in 2004 still useful

Liquidia to explore PRINT particle technology with PATH Malaria Vaccine Initiative

Topical cream used to treat skin diseases activates two distinct neuronal signaling pathways

Researchers identify immune cell population that acts as body's border patrol with the outside world

Human Vaccines journal publishes paper on Inovio's new DNA vaccine delivery technology

Technique that cleared mouse of HIV-like virus sparks hope for new therapy

Cell signaling hormone boosts immune response to clear HIV-like infection

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Immune protein exacerbates skin cancer due to sun exposure: Study

Researchers discover potential vaccine capable of reducing H. pylori colonization

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Scientists discover breast cancer cells that dodge immune system, promote tumor growth

New compound appears to prevent pain crises in sickle cell disease: GHSU

Positive interim results from H5N1 Avian Influenza VLP vaccine Phase II human clinical trial

Positive interim results from Medicago's Phase II clinical trial of H5N1 Avian Influenza VLP vaccine

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News